Captor Therapeutics Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety covalently linked to an induced myeloid leukemia cell differentiation protein MCL-1-targeting moiety through a linker.
Pfizer Inc. has identified nonstructural protein 3 (nsp3; PLpro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 (COVID-19) infection.
Senya Pharmaceuticals Inc. has described NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of neurological disorders.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has divulged myeloperoxidase inhibitors reported to be useful for the treatment of cardiovascular disorders.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized antibody-drug conjugates consisting of anti-B7-H3 antibodies covalently linked to cytotoxic drugs reported to be useful for the treatment of cancer.
In the first patenting to have been published in the name of Lo Biosciences Inc., the company’s co-founder and CEO Sasank Vemulapati seeks further protection for their development of a device and method that helps eliminate time, distance, and cost as barriers between patients and their next blood test, by allowing patients to collect laboratory quality blood samples at home without the assistance of any health care professionals.
Uppthera Inc. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a serine/threonine-protein kinase PLK1 (STPK13) targeting moiety through a linker. They are reported to be useful for the treatment of cancer and neurological disorders.
Scientists at RMW Cho Group Ltd. and Venner Shipley LLP have divulged chlorin K derivatives acting as photosensitizers reported to be used in photodynamic therapy (PDT) and photodynamic diagnosis of cancer.